Real-world study of NGS in luspatercept therapy for myeloid neoplasm-related anemia

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500107518

Enrollment

Unknown

Registered

2025-08-13

Start date

2025-02-26

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myeloid tumors combined with anemia

Interventions

The SF3B1-positive group:None

The SF3B1-negative group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Diagnosis of myelodysplastic syndrome (low-risk or high-risk group opting for supportive care) and myeloproliferative neoplasms (PV, ET, PMF), as well as other types of chronic myeloid neoplasms (e.g., chronic myelomonocytic leukemia and other chronic myeloproliferative neoplasms/myelodysplastic neoplasms); 2.Concurrent anemia; 3.Signed informed consent; 4.Age over 18 years.

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to the active substance or any excipient is contraindicated; 2.Pregnancy.

Design outcomes

Primary

Measure	Time frame
Blood routine indicators;Red blood cell transfusion;	—

Countries

China

Contacts

Public ContactTingting Cui

Peking University Sixth Hospital

lingbing5621@163.com+86 10 64035566

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026